Bridging human genetics and community medicine: emerging applications for precision public health
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20262766Keywords:
Precision public health, Human genetics, Community medicine, Public health genomicsAbstract
Historically, human genetics and community medicine have evolved as separate disciplines. The domain of genetics has been on molecular mechanisms of disease and community medicine has traditionally been on prevention at the population level and health systems. Over the last two decades, advances in genomic technologies, falling sequencing costs and the expansion of large-scale biobanks have made it possible to integrate genetic insights into public health. This convergence has led to the development of precision public health, which seeks to improve disease prevention, risk stratification and health interventions at the population level. Moreover, in countries such as India, the distinct genetic diversity resulting from endogamy and founder effects points to the necessity of population-specific genomic approaches within public health frameworks. This review summarizes the existing evidence for the incorporation of human genetics into community medicine in the following areas: genetic epidemiology, population risk prediction, genetic screening across the life course, infectious disease genomics, pharmacogenomics, and genetic determinants of non-communicable diseases. It shows the potential of tools such as polygenic risk scores, pathogen genome sequencing and pharmacogenomic testing to enhance early detection, targeted prevention and rational therapeutics. The review also discusses the Indian context, with examples of national initiatives such as the Genome, India Project and the National Sickle Cell Elimination Mission as examples of translating genomic science to public health practice. Crucially, it addresses implementation challenges such as ancestry bias, ethical considerations, health system readiness, and the need for culturally sensitive community engagement.
References
Khoury MJ, Burke W, Thomson EJ. Genetics and public health: A framework for the integration of human genetics into public health practice. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease, Oxford Monographs on Medical Genetics (New York, 2000; online edn, Oxford Academic. 2009.
Jimenez-Silva C, Rivero R, Douglas J, Bouckaert R, Villabona-Arenas CJ, Atkins KE, et al. Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia. Commun Med. 2023;3(1):97.
Basu A, Sarkar-Roy N, Majumder PP. Genomic reconstruction of the history of extant populations of India reveals five distinct ancestral components and a complex structure. Proc Natl Acad Sci U S A. 2016;113(6):1594-9.
Sinha S, Seth T, Colah RB, Bittles AH. Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017–2026. J Community Genet. 2020;11(1):39-45.
Bhattacharyya C, Subramanian K, Uppili B, Biswas NK, Ramdas S, Tallapaka KB, et al. Mapping genetic diversity with the GenomeIndia project. Nat Genet. 2025;57(4):767-73.
National Sickle Cell Anaemia Elimination Mission. Guidelines & Training Materials. Available at: https://sickle.nhm.gov.in/home/guidelines. Accessed on 12 May 2026.
Union Minister Dr. Jitendra Singh convenes a joint meeting of Department of Biotechnology, AIIMS New Delhi, BIRAC, ICMR and Industry partners to review the indigenously developed HPV test kits for Cervical Cancer screening in India Calls Scientific Review of Indigenously Developed HPV Test Kits for Cervical Cancer Screening. Available at: http://www.pib.gov.in/PressReleseDetail.aspx?PRID=2123856®=3&lang=2. Accessed on 12 May 2026.
World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2021. Available at: https://www.who.int/publications/i/item/9789240030824. Accessed on 12 May 2026.
Khoury MJ. Genetic Epidemiology and the Future of Disease Prevention and Public Health. Epidemiol Rev. 1997;19(1):175-80.
Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018;170(1):189-96.
Moreno-Grau S, Vernekar M, Lopez-Pineda A, Mas-Montserrat D, Barrabés M, Quinto-Cortés CD, et al. Polygenic risk score portability for common diseases across genetically diverse populations. Hum Genomics. 2024;18(1):93.
Jha RK, Kaple M, Ambad RS, Dhok A, Anjankar A. Comprehensive Neonatal Screening for Genetic Disorders in Tribal Populations of Central India. J Pharm Bioallied Sci. 2024;16(Suppl 4):S4021-5.
Pandharipande A, Radhakrishnan N, Verma S, Chauhan VK, Baby EP, Srivastava A. Barriers to cascade screening and prenatal testing in families with genetic haematological diseases. J Rare Dis. 2025;4(1):18.
O’Sullivan JW, Ashley EA, Elliott PM. Polygenic risk scores for the prediction of cardiometabolic disease. Eur Heart J. 2023;44(2):89-99.
Rout M, Wander GS, Ralhan S, Singh JR, Aston CE, Blackett PR, et al. Assessing the prediction of type 2 diabetes risk using polygenic and clinical risk scores in South Asian study populations. Ther Adv Endocrinol Metab. 2023;14:20420188231220120.
Kachuri L, Chatterjee N, Hirbo J, Schaid DJ, Martin I, Kullo IJ, et al. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet. 2024;25(1):8-25.
CDC. ACCE Model Process for Evaluating Genetic Tests. 2022. Available at: https://archive.cdc.gov/ www_cdc_gov/genomics/gtesting/acce/index.htm. Accessed on 12 May 2026.
World Health Organization. Cancer - Screening and early detection. Available at: https://www.who.int/ europe/news-room/fact-sheets/item/cancer-screening -and-early-detection-of-cancer. Accessed on 12 May 2026.
Raveendran A, Chacko TJ, Prabhu P, Varma R, Lewis LE, Rao P, et al. Need and Viability of Newborn Screening Programme in India: Report from a Pilot Study. Int J Neonatal Screen. 2022;8(2):26.
Friedman JM, Cornel MC, Goldenberg AJ, Lister KJ, Sénécal K, Vears DF, et al. Genomic newborn screening: public health policy considerations and recommendations. BMC Med Genomics. 2017;10(1):9.
Jena RK, Sethy S, Dash PK, Behera M, Palande B, Dave U. Hemoglobin Variant Analysis and Its Comparison between Conventional High-performance Liquid Chromatography Using Whole Blood versus Dried Blood Spot: High-performance Liquid Chromatography. Indian J Public Health. 2025;69(3):280.
Mami DM, Romba M, Patrick M. The Surveillance in Infectious Disease Control Role of Genomic. Int J Adv Multidisc Res Stud. 2025;5(4):1608-15.
van der Made CI, Netea MG, van der Veerdonk FL, Hoischen A. Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. Genome Med. 2022;14(1):96.
Sun N, Lu Y, Li C, Jiang A, Liu L, Guo J. Genetic Risk of Different Populations in COVID-19 Susceptibility and Severity. Infect Drug Resist. 2025;18:5499-505.
Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income countries: current status and future directions. Expert Rev Anti Infect Ther. 2022;20(2):147-60.
Grubaugh ND, Ladner JT, Lemey P, Pybus OG, Rambaut A, Holmes EC, et al. Tracking virus outbreaks in the twenty-first century. Nat Microbiol. 2019;4(1):10-9.
Rigter T, Jansen ME, de Groot JM, Janssen SWJ, Rodenburg W, Cornel MC. Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective. Front Genet. 2020;11:10.
Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Front Pharmacol. 2023;18:14.
Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625-9.
Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6(5):418-26.
Nakkam N, Konyoung P, Amornpinyo W, Saksit N, Tiamkao S, Khunarkornsiri U, et al. Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine. Br J Clin Pharmacol. 2022;88(2):773-86.
Tiwattanon K, John S, Koomdee N, Jinda P, Rachanakul J, Jantararoungtong T, et al. Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/ Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand. Front Pharmacol. 2022;13:867490.
Matsuoka K. NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res. 2020;18(3):275-81.
Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73-7.
Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388-94.
Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell. 2019;177(1):26-31.
Hay SI, Ong KL, Santomauro DF, A B, Aalipour MA, Aalruz H, et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet. 2025;406(10513):1873-922.
Qi L, Cornelis MC, Zhang C, van Dam RM, Hu FB. Genetic predisposition, Western dietary pattern, and the risk of type 2 diabetes in men. Am J Clin Nutr. 2009;89(5):1453-8.
Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349-58.
Wang Y, Namba S, Lopera E, Kerminen S, Tsuo K, Läll K, et al. Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. Cell Genomics. 2023;3(1):100241.
Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343-52.
Chen D, Liu F, Yang C, Liang X, Shang Q, He W, et al. Association between the TPH1 A218C polymorphism and risk of mood disorders and alcohol dependence: evidence from the current studies. J Affect Disord. 2012;138(1–2):27-33.
Khoodoruth MAS, Estudillo-Guerra MA, Pacheco-Barrios K, Nyundo A, Chapa-Koloffon G, Ouanes S. Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization. Front Psychiatry. 2022;13:886918.
Lebowitz MS. The Implications of Genetic and Other Biological Explanations for Thinking about Mental Disorders. Hastings Cent Rep. 2019;49 Suppl 1(Suppl 1):S82-7.
Baek CH, Kim HJ, Park HY, Seo HY, Yoo H, Park JE. Influence of Biogenetic Explanations of Mental Disorders on Stigma and Help-Seeking Behavior: A Systematic Review and Meta-Analysis. J Korean Med Sci. 2022;38(3):e25.
Traylor M, Rutten-Jacobs LCA, Holliday EG, Malik R, Sudlow C, Rothwell PM, et al. Differences in Common Genetic Predisposition to Ischemic Stroke by Age and Sex. Stroke. 2015;46(11):3042-7.
Downloads
Published
How to Cite
Issue
Section
